Article
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
The Lancet. Oncology - 1 Jan 2025
Santarsieri Anna, Mitchell Emily, Pham My H, Sanghvi Rashesh, Jablonski Janina, Lee-Six Henry, Sturgess Katherine, Brice Pauline, Menne Tobias F, Osborne Wendy, Creasey Thomas, Ardeshna Kirit M, Baxter Joanna, Behan Sarah, Bhuller Kaljit, Booth Stephen, Chavda Nikesh D, Collins Graham P, Culligan Dominic J, Cwynarski Kate, Davies Andrew, Downing Abigail, Dutton David, Furtado Michelle, Gallop-Evans Eve, Hodson Andrew, Hopkins David, Hsu Hannah, Iyengar Sunil, Jones Stephen G, Karanth Mamatha, Linton Kim M, Lomas Oliver C, Martinez-Calle Nicolas, Mathur Abhinav, McKay Pamela, Nagumantry Sateesh K, Phillips Elizabeth H, Phillips Neil, Rudge John F, Shah Nimish K, Stafford Gwyneth, Sternberg Alex, Trickey Rachel, Uttenthal Benjamin J, Wetherall Natasha, Zhang Xiao-Yin, McMillan Andrew K, Coleman Nicholas, Stratton Michael R, Laurenti Elisa, Borchmann Peter, Borchmann Sven, Campbell Peter J, Rahbari Raheleh, Follows George A
Abstract excerpt
BACKGROUND: Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this...
Read the complete abstract on PubMed